Curated News
By: NewsRamp Editorial Staff
September 08, 2026
Synbio International Secures Exclusive Licensing Deal for Nutraceuticals
TLDR
- Synbio International secures exclusive US and Canada rights to MD PHD Wellness nutraceuticals, gaining a competitive edge in the wellness market.
- The agreement outlines Synbio handling branding and sales while MD PHD manages development and manufacturing, with profits shared after cost recovery.
- This partnership brings scientifically developed anti-anxiety nutraceuticals to market, potentially improving mental wellness for many.
- Synbio's new deal includes a nutraceutical from a doctor with two PhDs, blending nuclear physics and biomedical engineering.
Impact - Why it Matters
This news matters because it marks a significant strategic pivot for Synbio International, a company primarily known for its AI-driven mental health software. By partnering with MD PHD Wellness, Synbio is diversifying its revenue streams and entering the booming nutraceutical market, which is projected to continue rapid growth. For investors, this agreement offers a clearer path to near-term commercial revenue, potentially enhancing shareholder value. For consumers, it signals the upcoming availability of a scientifically developed anti-anxiety nutraceutical, expanding wellness product options. The partnership also underscores a growing trend of technology companies leveraging established expertise to accelerate market entry, which could reshape competitive dynamics in both the nutraceutical and digital health sectors.
Summary
Synbio International, Inc. (OTC: SYIN) has announced a strategic licensing, manufacturing, supply, and revenue sharing agreement with MD PHD Wellness, Inc., securing exclusive rights to commercialize MD PHD's proprietary nutraceutical formulations across the United States and Canada. This partnership, highlighted in a NEWMEDIAWIRE release, brings Synbio's first product to market: an anti-anxiety nutraceutical to be sold under its Healing Force™ brand. The agreement not only provides immediate access to a flagship product but also establishes a framework for future product rollouts, significantly accelerating Synbio's revenue generation without the time and cost of in-house development.
Under the terms, MD PHD Wellness will manage product development, manufacturing, quality assurance, and supply chain, while Synbio handles branding, marketing, sales, and distribution. Profits will be shared after recovering approved costs. Synbio's CEO, Claudio Solitario, called the agreement a 'transformational milestone,' emphasizing the efficient, scalable business model that leverages MD PHD's scientific expertise and Synbio's commercialization strengths. The initial product is backed by the scientific leadership of Dr. Robert Lawrence, a physician and scientist with two PhDs, and Dr. David Anderson, a co-founder with extensive research experience, ensuring the formulations are scientifically developed. This move aligns with Synbio's dual-track strategy of generating near-term revenue from wellness products while advancing its longer-term AI-driven mental health technologies.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Synbio International Secures Exclusive Licensing Deal for Nutraceuticals
